{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-010748","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.304242+00:00","generated_at":"2026-05-27T01:50:23.914688+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LYMPHIR assigned permanent J-code J9161 by CMS, effective April 1, 2025","bullets":["LYMPHIR (denileukin diftitox-cxdl) received permanent HCPCS J-code J9161 for IV use, 1 microgram.","J-code effective April 1, 2025, for claims submission by healthcare providers.","Code facilitates billing and reimbursement for commercial and government insurance (VA, DoD, Medicare).","Chairman Leonard Mazur states milestone supports patient access and coding clarity."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-010748","json":"https://secwatch.observer/filing/0001213900-25-010748.json","markdown":"https://secwatch.observer/filing/0001213900-25-010748.md","text":"https://secwatch.observer/filing/0001213900-25-010748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/0001213900-25-010748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/ea0230157-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:50:23.914688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}